TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal GST tagged recombinant human FGFR2 (400 to 821 residues) expressed in an Sf9 infected baculovirus expression system using bi...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal GST tagged recombinant human FGFR2 (400 to 821 residues) expressed in an Sf9 infected baculovirus expression system using bi...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant human FGFR1 using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition an...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of N-terminal GST tagged recombinant human FGFR2 (400 to 821 residues) expressed in an Sf9 infected baculovirus expression system using bi...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibition of recombinant human FGFR1 using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition an...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibition of recombinant human FGFR3 V555M mutant using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrat...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of N-terminal GST tagged recombinant human FGFR2 (400 to 821 residues) expressed in an Sf9 infected baculovirus expression system using bi...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 4(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.90nMAssay Description:Inhibition of recombinant human FGFR4 (460 to 802 residues) using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant human FGFR1 using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition an...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.20nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.60nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.60nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.70nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Inhibition of recombinant human FGFR3 V555M mutant using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrat...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4.60nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 5.20nMAssay Description:Inhibition of recombinant human FGFR3 V555M mutant using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrat...More data for this Ligand-Target Pair
Affinity DataIC50: 5.40nMAssay Description:Inhibition of TEL-FGFR3 in mouse BaF3 cells incubated for 125 mins by plate reader analysisMore data for this Ligand-Target Pair
Affinity DataIC50: 5.5nMAssay Description:Inhibition of TEL-FGFR3 in mouse BaF3 cells incubated for 125 mins by plate reader analysisMore data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6.10nMAssay Description:Inhibition of recombinant human FGFR3 V555M mutant using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrat...More data for this Ligand-Target Pair
Affinity DataIC50: 7.20nMAssay Description:Inhibition of TEL-FGFR3 in mouse BaF3 cells incubated for 125 mins by plate reader analysisMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of wild type partial length human FLT3 (V592 to Y969 residues) expressed in bacterial expression system using Ulight-p70S6K peptide substr...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8.10nMAssay Description:Inhibition of recombinant human FGFR1 using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition an...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: <10nMAssay Description:The inhibitor potency of the exemplified compounds was determined in an enzyme discontinuous assay that measures peptide phosphorylation using FRET m...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: <10nMAssay Description:The inhibitor potency of the exemplified compounds was determined in an enzyme discontinuous assay that measures peptide phosphorylation using FRET m...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: <10nMAssay Description:The inhibitor potency of the exemplified compounds was determined in an enzyme discontinuous assay that measures peptide phosphorylation using FRET m...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: <10nMAssay Description:The inhibitor potency of the exemplified compounds was determined in an enzyme discontinuous assay that measures peptide phosphorylation using FRET m...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: <10nMAssay Description:The inhibitor potency of the exemplified compounds was determined in an enzyme discontinuous assay that measures peptide phosphorylation using FRET m...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: <10nMAssay Description:The inhibitor potency of the exemplified compounds was determined in an enzyme discontinuous assay that measures peptide phosphorylation using FRET m...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL